Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
11.66
-0.34 (-2.83%)
Feb 21, 2025, 4:00 PM EST - Market closed
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Bicycle Therapeutics stock have an average target of 33.25, with a low estimate of 15 and a high estimate of 60. The average target predicts an increase of 185.16% from the current stock price of 11.66.
Analyst Consensus: Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Hold Reiterates $15 | Hold | Reiterates | $15 | +28.64% | Jan 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +183.02% | Jan 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +174.44% | Jan 13, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $32 → $26 | Buy | Maintains | $32 → $26 | +122.98% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $55 → $33 | Strong Buy | Maintains | $55 → $33 | +183.02% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
38.05M
from 26.98M
Increased by 41.07%
Revenue Next Year
31.19M
from 38.05M
Decreased by -18.03%
EPS This Year
-3.08
from -5.08
EPS Next Year
-3.63
from -3.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 47.3M | 63.0M | 145.1M | |||
| Avg | 38.1M | 31.2M | 47.0M | |||
| Low | 33.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 75.2% | 65.6% | 365.1% | |||
| Avg | 41.1% | -18.0% | 50.6% | |||
| Low | 24.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.97 | -3.12 | -2.82 | |||
| Avg | -3.08 | -3.63 | -4.19 | |||
| Low | -3.38 | -4.18 | -5.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.